Objectives: this study aimed to evaluate new tools to diagnose invasive aspergillosis (IA) directly from bronchoalveolar lavage (BAL) samples.
INTRODUCTION
Immunocompromised patients are increasingly frequent, either because of hematological malignancies, or of non-hematological conditions such as solid-organ transplantation, chronic pulmonary diseases, long-term corticosteroid therapy, and stay in intensive care unit (ICU). Despite major progresses in their medical management, invasive aspergillosis (IA) remains a major cause of morbidity and mortality (1) . The timely and accurate diagnosis of active Aspergillus infection is eagerly required to initiate on time an adequate targeted antifungal therapy (2) . However, IA definite diagnosis is still challenging, as clinical and radiological manifestations are most often unspecific. The European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) recommended using microbiological criteria (3, 4) , such as the histological evidence of tissue infiltration, although rarely obtained, and mycological culture, although positive in only 50% of patients (5, 6) . This shortcoming has fuelled an interest in non-culture-based diagnostic techniques applied directly in clinical samples, particularly for non-hematological patients, such as antigen detection (galactomannan (GM), beta-1,3-D glucan) by enzyme-linked immuno-sorbent assay (ELISA), or PCRbased assays targeting the identification of Aspergillus spp. or of genes coding for triazole resistance. Numerous PCR-based assays able to detect Aspergillus spp. DNA with a high performance have recently been developed (7) (8) (9) (10) . Many centers include now PCR-based algorithms assays in their clinical management. However, data on the relevance of such molecular detection assays in bronchoalveolar (BAL) samples are still poor, preventing their inclusion in disease-defining criteria. Reported sensitivities of PCR assays in BAL have been highly variable, ranging from 36 to 95% (11) (12) (13) (14) , mainly because of differences in assay characteristics, population evaluated (hematological versus non-hematological patients), and doubts in IA diagnosis.
In addition, the treatment efficacy might be hampered by resistance to antifungals, as it is spreading in Europe (15) , as in South-America and Asia (16, 17) . In France, the incidence of resistant A. fumigatus isolates has been reported to be still low in the immunocompromised population (about 1% (18) ), whereas in chronically colonized patients the incidence of azole resistant strains can reach 8-12% as observed in our center and others (19) . Identification of azole resistance in Aspergillus fumigatus is conventionally based on minimal inhibitory concentration (MIC) determination, which necessitates to recover the strain in culture. Triazole-resistant isolates can also be detected by the identification of mutations in the cyp51A gene. fumigatus resistant strains have been related to a higher mortality rate, due to a delayed initiation of adequate treatment (23) . In this context, commercial kits targeting both A. fumigatus and cyp51A genes have been recently marketed, but their evaluation on clinical samples IA population is still scarce (24, 25) .
Our study aimed to assess the contribution of two in-house Aspergillus real-time PCR assays and of two commercial resistance multiplex assays (AsperGenius 
MATERIALS AND METHODS

Patients and study design
For this prospective study, all consecutive patients with suspected IA who underwent standard bronchoscopy with BAL at Rennes University Hospital (France) were included. Redundant samples for a unique clinical episode were excluded. Patients were classified as having proven, probable, possible IA, or no IA, according to the revised EORTC/MSG case definitions (2) .
BAL fluid samples processing
BAL fluid specimens were divided into 3 aliquots to perform culture, GM detection assay and PCR assays, respectively. For culture, 5-10 mL were centrifuged and the resuspended pellet (about 200µL) was directly inoculated on 2 conventional fungal media incubated at 30°C and 37°C for 8 days. Mold isolates from cultures were identified by macroscopic and microscopic examinations. For PCR assays, 1 mL of plain BAL was centrifuged and DNA was extracted from the pellet, using the QIAamp ® DNA minikit (Qiagen) according to manufacturer's recommendations. For ELISA, the aliquot was 390 µL, according to manufacturer recommendations.
Susceptibility testing
Itraconazole (ITC) and voriconazole (VRC) susceptibility of A. fumigatus strains isolated from IA samples was determined using Etest ® strips according to the manufacturer's instructions (bioMérieux, France), after 48h of incubation at 30°C. Azole resistance was assessed for MIC >2mg/mL for ITC and VRC according to EUCAST breakpoints v.8.0.
In-house Aspergillus PCR assays
BAL DNA extracts were tested using two real-time "in-house" PCR assays. When discrepant results with other tests (culture or GM) were observed, DNA was retested with both PCR assays.
The first PCR assay ("Af-mito") amplified a 196-bp sequence of A. fumigatus mitochondrial gene, as previously described (26) . The second PCR assay ("28S") targeted a 67-bp sequence of the A. fumigatus 28S rRNA gene, using primers and probe as previously published (27 
Galactomannan (GM) Platelia Aspergillus assay
The sandwich ELISA for BAL GM detection (Platelia Aspergillus ® ; Bio-Rad, Marnes-la-Coquette, France) was performed according to the manufacturer's recommendations, on a 390µL aliquot of BAL sample. For the classification of patients, the BAL was considered as positive when optical density index (ODI) was≥ 0.8, if
concomitant serum GM was positive (ODI ≥0.5), and ≥1.0 when serum GM was negative or unavailable.
Beta-tubulin sequencing
Identification of Aspergillus species other than fumigatus was confirmed by beta-tubulin gene typing, using primers bt2a and bt2b (28) . Amplification reaction and subsequent sequencing were performed as previously described (29) . Bidirectional sequences were analyzed using Seqscape ® software and submitted to GenBank public database by using the BLAST Search program for species identification.
ITS1-ITS2 sequencing
Identification of Scedosporium from BAL sample was confirmed by ITS1-ITS2 typing, using the primers ITS1
and ITS4. The protocol was similar as described above (28, 29) .
Statistical methods.
Data analysis was performed using GraphPad PRISM ® v. 5.02 software. Categorial variables were compared using the χ 2 test or Fisher's exact test. A p-value of 0.05 was considered to be statistically significant.
RESULTS
Patient characteristics
As depicted in Figure 1 , within 3 years (from January 2012 to December 2014), a total of 1,555 BAL, fluid samples (1,336 patients) were processed, including 413 samples collected from immunocompromised patients with clinical symptoms or radiological signs compatible with invasive fungal infection. Non-redundant BAL fluid specimens of 387 patients at high risk for IA were analyzed in this study.
According to the EORTC-MSG criteria, 61 patients were diagnosed with IA (1 proven, 37 probable, 23 possible cases), whereas the diagnosis of IA was excluded for 326 patients. The distribution of the patients according to their infection status and underlying conditions is presented in Table 1 . Twenty-seven out of 61 patients (44%)
were hospitalized in intensive care unit and 22 (36%) were in hematology unit.
Diagnostic performance of Aspergillus fumigatus PCR assays
The sensitivity of the 28S PCR assay was higher than that of Af-mito PCR (71.1% versus 60.5%), whereas its specificity for IA was 92.8% (324/349), i.e., lower than that of Af-mito PCR (95.4%, 333/349)( Table 2 ). It was interesting to note that in the no-IA group, 10 out of the 16 28S PCR positive BAL were from patients with chronic pulmonary disease, as aspergilloma or CNPA in 4 cases. These positive assays are consistent with
Aspergillus colonization and could not reasonably be considered as false positive results. The combination of both PCRs led to a slight increase of sensitivity (73.7%) with similar specificity (92.3%). By contrast, mycological cultures allowed to diagnose only 18/38 proven or probable IA (47.4%).
In BAL from patients with IA, commercial multiplex assays showed roughly similar results than in-house PCRs.
MycoGenie ® had the highest sensitivity (73.7%). The AsperGenius ® assay had a sensitivity of 60.5% and 68.4%
for A. fumigatus and Aspergillus spp. detection, respectively.
Interestingly, combinations of any PCR assay to current EORTC/MSG criteria (GM detection and culture in BAL) led to an increase of sensitivity (from 92.1% to 97.4 or 100% depending the PCR assay), without significant decrease of specificity (Table 2 ).
Of the twenty-two samples grown positive for A. fumigatus, Af-mito PCR was positive in 19/22 (86%) and 28S PCR in 20/22 (91%) ( Table 3) typing from the clinical specimen), suggesting that none of them is 100% specific for A. fumigatus.
Resistance screening using commercial PCR assays
A. fumigatus susceptibility to azole was investigated in the 61 samples from IA patients. Mycogenie ® PCR assay did not detect any TR34 or L98H mutation in the 37 positive samples for A. fumigatus target.
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No resistance marker was detected with Aspergenius ® assay either. However, we noticed that TR34, L98H, T289A and Y121F regions were successfully amplified in only 16 of the 29 samples with positive A. fumigatus detection, regardless of wild-type or mutated allele ( 
Performance of tests according to the clinical background
As displayed in Table 5 , sensitivity of culture combined to BAL GM and Af-mito PCR was significantly lower in patients with hematological malignancy (n=41) compared to the other patients (n=20), with estimated values decreasing from 85% to 43.9%, and 70% to 36.6%, respectively (p<0.01, p<0.05, respectively). Indeed, the sensitivity of Af-mito PCR was significantly reduced in neutropenic group (30% versus 64.5%, p<0.05) compared to non-neutropenic patients. Similarly, a previous exposure to mold-active antifungal agents (as prophylactic or curative treatment) lowered the sensitivity of all tests for Aspergillus detection ( 
DISCUSSION
In this 3-year prospective study, the diagnosis of IA was considered as proven or probable for 38 of 387 immunocompromised patients (9.8%) based on conventional techniques. When PCR was tested directly in BAL samples, its sensitivity was higher than that of culture, but lower than that of GM detection. Mycogenie ® PCR assay had a good sensitivity for IA diagnosis (73.7%), followed by Aspergenius ® PCR (68.4%). Of the two inhouse PCRs, the 28S PCR had the highest sensitivity, compared to Af-mito PCR (71.1% versus 60.5%). This difference was expected, based on A. fumigatus genome structure. Indeed while the copy number of the mitochondrial genome relative to the nuclear genome was estimated to be 12 (30), the ribosomal gene was shown to be repeated in 38 to 91 copies, varying according to the strain (31, 32) . A previous study on AsperGenius ® assay in BAL from hematological population, reported a higher sensitivity (84%) (24) and another assay (MycAssay ® Aspergillus) yielded sensitivity until 95% (12, 33) ; it could possibly be related to a slightly different use of antifungals at this time.
Currently, PCR in BAL is not included in the criteria for classification of IA. Although BAL is frequently sampled in ICU patients, it is rare in hematological patients. In oncological-hematological patients, the increasing use of anti-Aspergillus chemoprophylaxis decreases the incidence but also the sensitivity of all diagnostic tests, as shown here. In our study, patients with hematological malignancy and/or allogeneic hematopoietic transplantation were more frequent in the group with possible IA; of note, the rate of patients receiving anti-Aspergillus prophylaxis was higher in this group. Conversely, solid organ transplantation was more frequent among patients with proven/probable IA (p<0.05). This work clearly demonstrates a superior value of PCR in BAL for non-hematological immunosuppressed patients. The value of Aspergillus detection in endotracheal aspirates of ICU patients was already exemplified by Blot et al (34) who proposed a specific algorithm. Here, we observed a high sensitivity with a good specificity for BAL biomarkers such as GM and PCR in non-hematological patients, particularly if combined. Combining PCR to current EORTC criteria increased sensitivity from 92% to 100%. Such increase in sensitivity confirm previous results (35, 36) .
In hematological patients, despite a moderate sensitivity of each test performed alone, we showed that combination of PCR with EORTC criteria was of particular interest increasing the weak sensitivity of EORTC criteria from 44% to 68%, and particularly an increase from 30% to 50% and from 27% to 54% in patients under antifungals treatment (curative, empirical or prophylaxis) or specifically antifungal prophylaxis, respectively.
These findings could lead to the inclusion of PCR among EORTC-MSG IA criteria (37) . In our cohort, taking the in-house 28S PCR for the definition of IA would have upgraded 3 episodes from "possible cases" to "probable cases". Indeed, including an earlier and more sensitive method to detect Aspergillus in tissues may facilitate the diagnosis of IA, and, in turn, improve its management and clinical outcome. In addition, the high predictive value of simultaneous detection of fungal DNA and of GM antigen could lead to a reevaluation of empirical antifungal therapy for a better adequacy and a limitation of their use (38) .
The specificity was excellent with all PCR assays (>92%). It should be noted that among the group of excluded IA, several patients had a chronic pulmonary aspergillosis or impaired pulmonary functions, which are known to increase the frequency of Aspergillus colonization. Indeed, of the 16 BAL with positive 28S PCR, we recorded 10 patients with aspergilloma, semi-invasive aspergillosis, or other etiology of chronic respiratory failure. Apart from PCR results, 6 of these patients had a typical imaging (aspergilloma) or a strongly positive detection of Aspergillus antibodies and precipitins, leading to a triazole therapy.
Although 28S PCR was described as specific for A. fumigatus, we observed cross-reaction with A. flavus and A.
ochraceus, two species already associated with IA in previous studies (6, 39, 40) . Considering this finding, the combination of both techniques appears valuable in case of strongly suspected aspergillosis with negative culture and GM detection. In this setting, as Aspergenius ® assay targets both Aspergillus sp and A. fumigatus, it could have been considered as a relevant tool for IA diagnosis. However, the poor sensitivity observed here is a serious limitation to its use.
Apart ensuring PCR standardization, MycoGenie ® and AsperGenius ® kits are able to simultaneously detect hotspot cyp51A mutations associated with A. fumigatus triazole resistance directly from clinical samples. We did not detect any cyp51A mutation in our positive samples, and it was correlated with in vitro susceptibility testing results, when available. This finding is consistent with the apparent low azole resistance prevalence in immunocompromised patients in France (around 1%) (18) . However, we underlined a substantial poor sensitivity of cyp51A gene detection, mainly due to the presence of a single copy cyp51A gene in each fungal cell. This limiting factor has been previously raised in several reports using in-house molecular typing methods (22, 41) . This is especially a concern in samples from immunocompromised patients with a low fungal burden, moreover when an effective antifungal therapy has been initiated before sampling.
Here, we could not strictly rule out any resistant fungi, since these molecular screening focus only on a few hotspot single polynucleotide polymorphisms, and because several cyp51A-independent mechanisms have been reported to contribute to azole resistance (42) . In addition, rare cryptic species in Aspergillus genus responsible for IA are increasingly reported. Indeed, attention should be paid to these fungi, with treatment failure likely due to their low intrinsic susceptibility to some antifungals, especially triazole therapy (43) (44) (45) : quadruplex real-time PCR assay which targets A. fumigatus (28SrRNA gene), TR34, L98H, and an internal control to monitor sample inhibition. A result was considered as positive when a signal was detected at Ct<45. 
